Literature DB >> 26254398

Relation of Vitamin E and Selenium Exposure to Prostate Cancer Risk by Smoking Status: A Review and Meta-Analysis.

Yeunjung Kim1, Jingkai Wei2, Jessica Citronberg3, Terryl Hartman4, Veronika Fedirko4, Michael Goodman4.   

Abstract

BACKGROUND: Epidemiological studies of selenium and vitamin E, two antioxidants hypothesized to reduce prostate cancer risk, have shown no discernible benefit. It has been proposed, however, that tobacco smoking may modify the effect of these nutrients.
MATERIALS AND METHODS: We performed a meta-analysis of studies evaluating the relation of vitamin E and selenium exposure to prostate cancer risk in never smokers vs. ever smokers and, when feasible, former and current smokers. Overall and stratum-specific meta-risk ratios (meta-RRs) and 95% confidence intervals (CIs) were calculated using random-effects models.
RESULTS: A total of 21 studies have met the inclusion criteria. Meta-RR (95% CI) estimates of prostate cancer associated with vitamin E use were 1.03 (0.95-1.11) in never smokers and 0.98 (0.90-1.07) in ever-smokers. For selenium, meta-RRs were 1.09 (0.78-1.52 and 0.76 (0.60-0.96) for never and ever-smokers, respectively; however, results for current smokers were weaker than those for former smokers. Sub-analyses according to different exposure assessment methods and outcome definitions produced similar results across strata.
CONCLUSION: The association between vitamin E and prostate cancer is not modified by smoking. Selenium exposure is associated with lower prostate cancer risk among ever-smokers; however, the lack of an association for current smokers indicates that this finding needs to be interpreted with caution. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Selenium exposure; Vitamin E; prostate cancer risk; smoking status

Mesh:

Substances:

Year:  2015        PMID: 26254398

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

Review 2.  ROS-modulated therapeutic approaches in cancer treatment.

Authors:  Muhammad Hassan Raza; Sami Siraj; Abida Arshad; Usman Waheed; Fahad Aldakheel; Shatha Alduraywish; Muhammad Arshad
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-24       Impact factor: 4.553

Review 3.  New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.

Authors:  Domenico Ferro; Francesco Baratta; Daniele Pastori; Nicholas Cocomello; Alessandra Colantoni; Francesco Angelico; Maria Del Ben
Journal:  Nutrients       Date:  2020-09-10       Impact factor: 5.717

4.  Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma.

Authors:  Noah C Peeri; Jordan H Creed; Gabriella M Anic; Reid C Thompson; Jeffrey J Olson; Renato V LaRocca; Sajeel A Chowdhary; John D Brockman; Travis A Gerke; L Burton Nabors; Kathleen M Egan
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.